Xeris Biopharma Holdings Inc
NASDAQ:XERS

Watchlist Manager
Xeris Biopharma Holdings Inc Logo
Xeris Biopharma Holdings Inc
NASDAQ:XERS
Watchlist
Price: 3.115 USD -1.11% Market Closed
Market Cap: 464.1m USD
Have any thoughts about
Xeris Biopharma Holdings Inc?
Write Note

Intrinsic Value

The intrinsic value of one XERS stock under the Base Case scenario is 3.039 USD. Compared to the current market price of 3.115 USD, Xeris Biopharma Holdings Inc is Overvalued by 2%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

XERS Intrinsic Value
3.039 USD
Overvaluation 2%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Xeris Biopharma Holdings Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for XERS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about XERS?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Pharmaceuticals Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Xeris Biopharma Holdings Inc

Provide an overview of the primary business activities
of Xeris Biopharma Holdings Inc.

What unique competitive advantages
does Xeris Biopharma Holdings Inc hold over its rivals?

What risks and challenges
does Xeris Biopharma Holdings Inc face in the near future?

Summarize the latest earnings call
of Xeris Biopharma Holdings Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Xeris Biopharma Holdings Inc.

Provide P/S
for Xeris Biopharma Holdings Inc.

Provide P/E
for Xeris Biopharma Holdings Inc.

Provide P/OCF
for Xeris Biopharma Holdings Inc.

Provide P/FCFE
for Xeris Biopharma Holdings Inc.

Provide P/B
for Xeris Biopharma Holdings Inc.

Provide EV/S
for Xeris Biopharma Holdings Inc.

Provide EV/GP
for Xeris Biopharma Holdings Inc.

Provide EV/EBITDA
for Xeris Biopharma Holdings Inc.

Provide EV/EBIT
for Xeris Biopharma Holdings Inc.

Provide EV/OCF
for Xeris Biopharma Holdings Inc.

Provide EV/FCFF
for Xeris Biopharma Holdings Inc.

Provide EV/IC
for Xeris Biopharma Holdings Inc.

Show me price targets
for Xeris Biopharma Holdings Inc made by professional analysts.

What are the Revenue projections
for Xeris Biopharma Holdings Inc?

How accurate were the past Revenue estimates
for Xeris Biopharma Holdings Inc?

What are the Net Income projections
for Xeris Biopharma Holdings Inc?

How accurate were the past Net Income estimates
for Xeris Biopharma Holdings Inc?

What are the EPS projections
for Xeris Biopharma Holdings Inc?

How accurate were the past EPS estimates
for Xeris Biopharma Holdings Inc?

What are the EBIT projections
for Xeris Biopharma Holdings Inc?

How accurate were the past EBIT estimates
for Xeris Biopharma Holdings Inc?

Compare the revenue forecasts
for Xeris Biopharma Holdings Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Xeris Biopharma Holdings Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Xeris Biopharma Holdings Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Xeris Biopharma Holdings Inc compared to its peers.

Compare the P/E ratios
of Xeris Biopharma Holdings Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Xeris Biopharma Holdings Inc with its peers.

Analyze the financial leverage
of Xeris Biopharma Holdings Inc compared to its main competitors.

Show all profitability ratios
for Xeris Biopharma Holdings Inc.

Provide ROE
for Xeris Biopharma Holdings Inc.

Provide ROA
for Xeris Biopharma Holdings Inc.

Provide ROIC
for Xeris Biopharma Holdings Inc.

Provide ROCE
for Xeris Biopharma Holdings Inc.

Provide Gross Margin
for Xeris Biopharma Holdings Inc.

Provide Operating Margin
for Xeris Biopharma Holdings Inc.

Provide Net Margin
for Xeris Biopharma Holdings Inc.

Provide FCF Margin
for Xeris Biopharma Holdings Inc.

Show all solvency ratios
for Xeris Biopharma Holdings Inc.

Provide D/E Ratio
for Xeris Biopharma Holdings Inc.

Provide D/A Ratio
for Xeris Biopharma Holdings Inc.

Provide Interest Coverage Ratio
for Xeris Biopharma Holdings Inc.

Provide Altman Z-Score Ratio
for Xeris Biopharma Holdings Inc.

Provide Quick Ratio
for Xeris Biopharma Holdings Inc.

Provide Current Ratio
for Xeris Biopharma Holdings Inc.

Provide Cash Ratio
for Xeris Biopharma Holdings Inc.

What is the historical Revenue growth
over the last 5 years for Xeris Biopharma Holdings Inc?

What is the historical Net Income growth
over the last 5 years for Xeris Biopharma Holdings Inc?

What is the current Free Cash Flow
of Xeris Biopharma Holdings Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Xeris Biopharma Holdings Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Xeris Biopharma Holdings Inc

Current Assets 170.3m
Cash & Short-Term Investments 77.6m
Receivables 42.4m
Other Current Assets 50.3m
Non-Current Assets 161.4m
PP&E 28.7m
Intangibles 127.2m
Other Non-Current Assets 5.5m
Current Liabilities 75.5m
Accounts Payable 5.8m
Accrued Liabilities 68.3m
Other Current Liabilities 1.4m
Non-Current Liabilities 275.5m
Long-Term Debt 230.5m
Other Non-Current Liabilities 45.1m
Efficiency

Earnings Waterfall
Xeris Biopharma Holdings Inc

Revenue
181.4m USD
Cost of Revenue
-29.5m USD
Gross Profit
151.9m USD
Operating Expenses
-189.1m USD
Operating Income
-37.2m USD
Other Expenses
-22.4m USD
Net Income
-59.6m USD

Free Cash Flow Analysis
Xeris Biopharma Holdings Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

XERS Profitability Score
Profitability Due Diligence

Xeris Biopharma Holdings Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

41/100
Profitability
Score

Xeris Biopharma Holdings Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

XERS Solvency Score
Solvency Due Diligence

Xeris Biopharma Holdings Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Positive Net Debt
36/100
Solvency
Score

Xeris Biopharma Holdings Inc's solvency score is 36/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

XERS Price Targets Summary
Xeris Biopharma Holdings Inc

Wall Street analysts forecast XERS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for XERS is 4.76 USD with a low forecast of 3.03 USD and a high forecast of 6.3 USD.

Lowest
Price Target
3.03 USD
3% Downside
Average
Price Target
4.76 USD
53% Upside
Highest
Price Target
6.3 USD
102% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for XERS?

Click here to dive deeper.

Dividends

Xeris Biopharma Holdings Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for XERS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

XERS News

Profile

Xeris Biopharma Holdings Inc Logo
Xeris Biopharma Holdings Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

463.9m USD

Dividend Yield

0%

Description

Xeris Biopharma Holdings, Inc. is a holding company. The company is headquartered in Chicago, Illinois and currently employs 294 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The firm has three commercial products: Gvoke, Keveyis and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Its product candidate also includes Ogluo (EU), Self-Administered Glucagon for prevention, Levothyroxine and XP-9164. The firm uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products.

Contact

ILLINOIS
Chicago
180 N. Lasalle Street, Suite 1600
+18444455704.0

IPO

2018-06-21

Employees

294

Officers

CEO & Director
Mr. John P. Shannon
Chief Financial Officer
Mr. Steven M. Pieper
Chief Legal Officer & Corporate Secretary
Ms. Beth P. Hecht J.D.
Senior Advisor
Mr. Paul R. Edick
Senior VP of Global Development & Medical Affairs
Dr. Kenneth E. Johnson Pharm. D., Pharm.D.
Senior Vice President of Investor Relations & Corporate Communications
Ms. Allison Wey
Show More
SVP of Quality and Chief Compliance & Risk Officer
Mr. Brian Conner
Senior Vice President of Human Resources
Ms. Kendal Korte
Chief Commercial Officer
Mr. Kevin McCulloch
Show Less

See Also

Discover More
What is the Intrinsic Value of one XERS stock?

The intrinsic value of one XERS stock under the Base Case scenario is 3.039 USD.

Is XERS stock undervalued or overvalued?

Compared to the current market price of 3.115 USD, Xeris Biopharma Holdings Inc is Overvalued by 2%.

Back to Top